COVID-19NCT07722000
Different Treatment Options Used for Post Covid-19 Syndrome
A study testing Ginkgo biloba, Piracetam and Ginkgo biloba and Piracetam in people with COVID-19 and Post COVID-19 Syndrome, run by Beni-Suef University at 1 site in Egypt.
Trial summary
This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- COVID-19, Post COVID-19 Syndrome, Ginkgo Biloba
- What is being tested?
- Ginkgo biloba, Piracetam and Ginkgo biloba and Piracetam
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Feb 2021to 1 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged from 18 to 70 years.
- Both sexes.
- Positive diagnosis of COVID-19 within the last 3 months in relation to the time of assessment (COVID-19 diagnosis had been previously confirmed by RT-PCR nasal swab testing as part of routine clinical evaluation before enrollment into the study).
Who cannot join
- Patients with other non-COVID-related chronic illnesses that could interfere with the assessment of post-viral symptoms.
- Patients with pre-existing neurological disorders that could affect cognitive function or fatigue assessment, including dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, or prior cerebrovascular stroke, patients with diagnosed psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, or anxiety disorders requiring ongoing pharmacological treatment.
- Patients with uncontrolled endocrine disorders, particularly uncontrolled diabetes mellitus or thyroid dysfunction.
- Patients with malignancy or receiving chemotherapy, radiotherapy, or immunosuppressive therapy during the study period.
- Patients with chronic fatigue syndrome, fibromyalgia, or other pre-existing fatigue-related disorders diagnosed prior to SARS-CoV-2 infection.
- Patients with substance abuse or alcohol dependence, pregnant or lactating women.
- Patients with known hypersensitivity or contraindications to Ginkgo biloba or piracetam.
- Patients with poor adherence to treatment or anticipated inability to complete follow-up visits.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Different Treatment Options Used for Post Covid-19 Syndrome
This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms.
Read the detailed description
COVID-19 is a disease caused by a new strain of coronavirus The COVID-19 virus is a new virus linked to the same family of viruses as severe acute respiratory syndrome (SARS) and some types of common cold. Symptoms can include fever, cough, and shortness of breath. In more severe cases, infection can cause pneumonia or breathing difficulties. More rarely, the disease can be fatal. These symptoms are similar to the flu (influenza) or the common cold, which are a lot more common than COVID-19.
The virus is transmitted through direct contact with respiratory droplets of an infected person (generated through coughing and sneezing). Individuals can also be infected from and touching surfaces contaminated with the virus and touching their face (e.g., eyes, nose, mouth).
- Conditions
- COVID-19, Post COVID-19 Syndrome, Ginkgo Biloba, Piracetam
- Being tested
- Ginkgo biloba, Piracetam, Ginkgo biloba and Piracetam
- Medical subject headings
- COVID-19, Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ginkgo bilobaDrug
Patients who received Ginkgo biloba alone.
PiracetamDrug
Patients who received piracetam alone.
Ginkgo biloba and PiracetamDrug
Patients who received a combination (Ginkgo biloba and Piracetam).
| Study group | Role | What they receive |
|---|---|---|
| Group I | Experimental | Patients who received Ginkgo biloba alone. Receives: Drug: Ginkgo biloba |
| Group II | Experimental | Patients who received piracetam alone. Receives: Drug: Piracetam |
| Group III | Experimental | Patients who received a combination (Ginkgo biloba and Piracetam). Receives: Drug: Ginkgo biloba and Piracetam |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mini-Mental State Examination (MMSE)
The Mini-Mental State Examination (MMSE) was used to assess global cognitive status. It evaluates orientation, immediate and delayed recall, attention and calculation, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores reflecting better cognitive function. Cognitive impairment was classified as mild (21-24), moderate (10-20), or severe (<10). The MMSE was administered in a face-to-face interview format
Measured: 1 year after the procedure
Secondary outcomes (3)
Fatigue Severity Scale
Fatigue Severity Scale (FSS) is a validated, widely used self-report instrument designed to quantify the severity and impact of fatigue on daily functioning over the previous seven days. It consists of nine statements covering aspects such as motivation, exercise-induced fatigue, physical functioning, and interference with work, social, and family life. For each item, patients rate their level of agreement on a 7-point scale where 1 indicates strong disagreement and 7 indicates strong agreement. Higher scores on the nine item values (ranging from 1.0 to 7.0) indicate more severe fatigue, with a mean score of 4.0 or higher considered indicative of moderate to severe fatigue. Sum score: total of all item values (9-63). Mean score: average of the 9 item values (1.0-7.0)
Measured: 1 year after the procedure
Changes in headache severity
Headache by visual analogue scale (VAS) was recorded was recorded at baseline, after 3 months, 6 months, and after 1 year. Pain was assessed by using visual analogue scale (VAS) which is presented as a 10 cm straight line reflecting the extremes of "no pain" and "worst pain. All patients included were followed longitudinally after initiation of treatment, with scheduled follow-up visits for 3 months, 6 months, and 12 months to assess persistence, improvement, or resolution of symptoms.
Measured: 1 year after the procedure
Prevalence of neurological manifestations
Prevalence of neurological manifestations related to post-COVID syndrome were recorded.
Measured: 1 year post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2026
- Study start1 Feb 2021
- Primary completion1 Dec 2023
- Study completion1 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Esraa Hussien Gomaa, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07722000
- Sponsor's protocol ID
- M 769
- Status last verified
- Jul 2026
- First submitted
- 19 Jul 2026
- Last updated
- 28 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Different Treatment Options Used for Post Covid-19 Syndrome
- ClinicalTrials.gov ID
- NCT07722000
- Acronym / sponsor ID
- M 769
- Conditions
- COVID-19, Post COVID-19 Syndrome, Ginkgo Biloba, Piracetam
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 1 Feb 2021 (actual)
- Primary completion
- 1 Dec 2023 (actual)
- Study completion
- 1 Dec 2023 (actual)
- First posted
- 23 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms.
Detailed description
COVID-19 is a disease caused by a new strain of coronavirus The COVID-19 virus is a new virus linked to the same family of viruses as severe acute respiratory syndrome (SARS) and some types of common cold. Symptoms can include fever, cough, and shortness of breath. In more severe cases, infection can cause pneumonia or breathing difficulties. More rarely, the disease can be fatal. These symptoms are similar to the flu (influenza) or the common cold, which are a lot more common than COVID-19.
The virus is transmitted through direct contact with respiratory droplets of an infected person (generated through coughing and sneezing). Individuals can also be infected from and touching surfaces contaminated with the virus and touching their face (e.g., eyes, nose, mouth).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group I | Experimental | Drug: Ginkgo bilobaPatients who received Ginkgo biloba alone. |
| Group II | Experimental | Drug: PiracetamPatients who received piracetam alone. |
| Group III | Experimental | Drug: Ginkgo biloba and PiracetamPatients who received a combination (Ginkgo biloba and Piracetam). |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients aged from 18 to 70 years.
- Both sexes.
- Positive diagnosis of COVID-19 within the last 3 months in relation to the time of assessment (COVID-19 diagnosis had been previously confirmed by RT-PCR nasal swab testing as part of routine clinical evaluation before enrollment into the study).
Key exclusion criteria (8 listed)
- Patients with other non-COVID-related chronic illnesses that could interfere with the assessment of post-viral symptoms.
- Patients with pre-existing neurological disorders that could affect cognitive function or fatigue assessment, including dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, or prior cerebrovascular stroke, patients with diagnosed psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, or anxiety disorders requiring ongoing pharmacological treatment.
- Patients with uncontrolled endocrine disorders, particularly uncontrolled diabetes mellitus or thyroid dysfunction.
- Patients with malignancy or receiving chemotherapy, radiotherapy, or immunosuppressive therapy during the study period.
- Patients with chronic fatigue syndrome, fibromyalgia, or other pre-existing fatigue-related disorders diagnosed prior to SARS-CoV-2 infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ginkgo bilobaPatients who received Ginkgo biloba alone. | Drug | Group I |
| PiracetamPatients who received piracetam alone. | Drug | Group II |
| Ginkgo biloba and PiracetamPatients who received a combination (Ginkgo biloba and Piracetam). | Drug | Group III |
Primary outcome
Mini-Mental State Examination (MMSE)
Time frame: 1 year after the procedure
The Mini-Mental State Examination (MMSE) was used to assess global cognitive status. It evaluates orientation, immediate and delayed recall, attention and calculation, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores reflecting better cognitive function. Cognitive impairment was classified as mild (21-24), moderate (10-20), or severe (<10). The MMSE was administered in a face-to-face interview format
3 secondary outcomes
Fatigue Severity Scale
Time frame: 1 year after the procedure
Changes in headache severity
Time frame: 1 year after the procedure
Prevalence of neurological manifestations
Time frame: 1 year post-procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ginkgo biloba, Piracetam and Ginkgo biloba and Piracetam in people with COVID-19 and Post COVID-19 Syndrome, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mini-Mental State Examination (MMSE) (time frame: 1 year after the procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.